

ABSTRACT

Therapeutics of bone resorption-associated diseases, which contain selective iNOS inhibitors as the active ingredient, are useful as a therapeutic of osteoporosis, a
5 bone mass-maintenance drug, a bone resorption retardant, an inhibitor of bone metastasis of cancer cells, a therapeutic of nephritis, a progression retardant of chronic renal failure, etc.